ALRT 1057, 9 CIS RETINOIC ACID IN PATIENTS W/ APML

ALRT 1057, 9 顺式视黄酸在 APML 患者中的应用

• 批准号: 6263731
• 负责人: DAN DOUER
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263731
• 关键词: clinical research; human subject; human therapy evaluation; myelogenous leukemia; neoplasm /cancer chemotherapy; retinoate; vitamin therapy

Acute promyelocytic (APL) treatment of patients has resulted in several complete remissions both in previously treated or newly diagnosed cases. The clinical safety profile of PANRETIN capsules is similar to the profile described for Tretinoin. The potential advantages of PANRETIN in APL is its effect on both types of retinoic acid receptors. PANRETIN wil be compared to Tretinoin capsules in induction of durable remissions in newly diagnosed APL cases.

急性早幼粒细胞（APL）治疗已使既往治​​疗或新诊断病例中的数个患者完全缓解。 PANRETIN 胶囊的临床安全性与维甲酸的临床安全性相似。 PANRETIN 在 APL 中的潜在优势在于它对两种类型的视黄酸受体都有作用。 将 PANRETIN 与维甲酸胶囊在新诊断 APL 病例诱导持久缓解方面进行比较。